No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Jun 12, 2024
On 12 June 2024, Boston-based Zumutor Biologics announced that it has commenced its open-label, first-in-human, multicentre, Ph 1 trial of ZM008 in patients with advanced solid tumours. The trial (NCT06451497) is evaluating ZM008 alone and in combination with...
Jun 11, 2024
On 11 June 2024, Japan’s Ono Pharma announced completion of its acquisition of US biopharmaceuticals company Deciphera for approximately $2.4 billion. Ono plans to leverage Deciphera's oncology research and development capabilities, as well as its sales presence in...
Jun 11, 2024
On 11 June 2024, Judge Kleeh of the US District Court for the Northern District of West Virginia made a permanent injunction order against Biocon in the dispute brought by Regeneron in relation to patents relating to aflibercept. The order is currently sealed. As...
Jun 11, 2024
On 11 June 2024, Alvotech announced that it has expanded its current partnership with STADA to include AVT03 (denosumab), biosimilar to Amgen’s Prolia®/Xgeva®. Under the agreement, STADA will be the sponsor of the Alvotech developed product, with semi-exclusive...
Jun 11, 2024
On 11 June 2024, Regeneron announced that the FDA approved its Kevzara® (sarilumab) for active polyarticular juvenile idiopathic arthritis (PJIA). Kevzara® is jointly developed by Regeneron and Sanofi under a global collaboration agreement. Kevzara® is approved in...
Jun 10, 2024
On 10 June 2024, Eisai and Biogen announced that the FDA has accepted Eisai’s Supplemental Biologics License Application (sBLA) for Leqembi® (lecanemab-irmb) for monthly intravenous maintenance dosing in treating early Alzheimer’s disease. The target PDUFA action...
Jun 6, 2024
On 6 June 2024, the Korea Biomedical Review reported that Celltrion has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for an additional dosing regimen and dose increase for RemsimaSC®...
Jun 4, 2024
At the American Society of Clinical Oncology (ASCO) conference, held from 31 May to 4 June 2024, Fresenius Kabi presented results of a Phase 3 study comparing its FKS518 with Amgen’s Prolia® (denosumab) in postmenopausal women with osteoporosis. FKS518 was shown to...
May 31, 2024
On 31 May 2024, Regeneron and Sanofi announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Dupixent® (dupilumab) as an add-on maintenance treatment for uncontrolled chronic obstructive...
May 30, 2024
On 30 May 2024, Samsung Bioepis announced that it will present a post-hoc analysis of the Phase 3 study results for its EpysqliTM (SB12), biosimilar to Alexion’s Soliris® (eculizumab), at the 29th European Hematology Association Congress to be held in Spain from 13-16...
May 30, 2024
On 30 May 2024, the Korea IT Times reported that Celltrion announced it received domestic approval from South Korea's Ministry of Food and Drug Safety for EydenzeltTM (CT-P42), biosimilar to Regeneron's Eylea® (aflibercept). Eydenzelt was approved for the same...
May 30, 2024
As previously reported, on 17 May 2024, a temporary 14 day restraining order was granted preventing Biocon from launching its Yesafili®, biosimilar to Regeneron’s Eylea® (aflibercept), in the US without a licence from Regeneron. The purpose of the temporary order was...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.